Amneal Pharmaceuticals, Inc. (AMRX)Healthcare | Drug Manufacturers - Specialty & Generic | Bridgewater, United States | NasdaqGS
13.02 USD
-0.24
(-1.810%) ⇩
(April 21, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 18, 2026, 10:51 p.m. EDT
Amneal appears fundamentally well-positioned for multi-year growth with a reasonable forward P/E (11.8x) and improving margins, backed by significant insider incentives and analyst upgrades. The deep value trap indicators (negative book value) are likely accounting artifacts common in pharmaceuticals, yet the price remains weak relative to its growth trajectory. However, the short-term chart is noisy and the forecast model suggests a slight downside bias (-3%); given the wide trading range (13.09–13.91) and high beta, your best bet is to ignore the short-term technicals and buy the dip for a medium-to-long-term hold, waiting for the projected rally to the $16.80–$18.00 target. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.074123 |
| AutoETS | 0.074494 |
| AutoTheta | 0.104274 |
| AutoARIMA | 0.150953 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 52% |
| H-stat | 3.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.133 |
| Excess Kurtosis | -1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 45095.523 |
| Revenue per Share | 9.633 |
| Market Cap | 4,153,367,296 |
| Trailing P/E | 59.18 |
| Forward P/E | 11.03 |
| Beta | 1.32 |
| Profit Margins | 2.39% |
| Website | https://www.amneal.com |
As of April 18, 2026, 10:51 p.m. EDT: Options flow shows aggressive speculative positioning in September 2026 calls (June options lean bullish on OTM volume), specifically the 15-strike ATM anchor. Near-term April/May shows heavy ITM call OI at the 12.5 strike, suggesting a floor or support play, while recent put activity is negligible except for low-volume deep OTM puts. The massive volume in June OTM calls indicates a bet on a post-earnings upside leg, while the lack of corresponding put positioning suggests low fear.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7835616 |
| Address1 | 400 Crossing Boulevard |
| Address2 | 3rd Floor |
| All Time High | 24.48 |
| All Time Low | 1.24 |
| Ask | 13.06 |
| Ask Size | 4 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,423,130 |
| Average Daily Volume3 Month | 2,617,632 |
| Average Volume | 2,617,632 |
| Average Volume10Days | 1,423,130 |
| Beta | 1.318 |
| Bid | 13.0 |
| Bid Size | 3 |
| Board Risk | 7 |
| Book Value | -0.225 |
| City | Bridgewater |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.02 |
| Current Ratio | 2.168 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.33 |
| Day Low | 12.955 |
| Debt To Equity | 45,095.523 |
| Display Name | Amneal Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,638,600 |
| Earnings Call Timestamp Start | 1,777,638,600 |
| Earnings Timestamp | 1,777,638,600 |
| Earnings Timestamp End | 1,777,638,600 |
| Earnings Timestamp Start | 1,777,638,600 |
| Ebitda | 644,270,016 |
| Ebitda Margins | 0.21341999 |
| Enterprise To Ebitda | 10.207 |
| Enterprise To Revenue | 2.178 |
| Enterprise Value | 6,575,808,000 |
| Eps Current Year | 0.99027 |
| Eps Forward | 1.18073 |
| Eps Trailing Twelve Months | 0.22 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 908 947 3146 |
| Fifty Day Average | 13.2065 |
| Fifty Day Average Change | -0.1864996 |
| Fifty Day Average Change Percent | -0.014121803 |
| Fifty Two Week Change Percent | 78.356155 |
| Fifty Two Week High | 15.42 |
| Fifty Two Week High Change | -2.3999996 |
| Fifty Two Week High Change Percent | -0.155642 |
| Fifty Two Week Low | 7.02 |
| Fifty Two Week Low Change | 6.0000005 |
| Fifty Two Week Low Change Percent | 0.8547009 |
| Fifty Two Week Range | 7.02 - 15.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,525,699,800,000 |
| Float Shares | 176,277,246 |
| Forward Eps | 1.18073 |
| Forward P E | 11.027077 |
| Free Cashflow | 197,065,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 8,700 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.37382 |
| Gross Profits | 1,128,460,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.44039002 |
| Held Percent Institutions | 0.49560001 |
| Implied Shares Outstanding | 318,999,016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,023-12-27 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. |
| Long Name | Amneal Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 4,153,367,296 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_38444119 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 72,057,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,156,557,178 |
| Number Of Analyst Opinions | 6 |
| Open | 13.26 |
| Operating Cashflow | 339,992,000 |
| Operating Margins | 0.14061 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 908 947 3120 |
| Previous Close | 13.26 |
| Price Eps Current Year | 13.147929 |
| Price Hint | 2 |
| Price To Book | -57.86667 |
| Price To Sales Trailing12 Months | 1.3758521 |
| Profit Margins | 0.02387 |
| Quick Ratio | 1.391 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -0.24 |
| Regular Market Change Percent | -1.80995 |
| Regular Market Day High | 13.33 |
| Regular Market Day Low | 12.955 |
| Regular Market Day Range | 12.955 - 13.33 |
| Regular Market Open | 13.26 |
| Regular Market Previous Close | 13.26 |
| Regular Market Price | 13.02 |
| Regular Market Time | 1,776,801,601 |
| Regular Market Volume | 1,050,886 |
| Return On Assets | 0.07324 |
| Revenue Growth | 0.115 |
| Revenue Per Share | 9.633 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 318,999,016 |
| Shares Percent Shares Out | 0.0226 |
| Shares Short | 7,193,959 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,920,253 |
| Short Name | Amneal Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0347 |
| Short Ratio | 3.18 |
| Source Interval | 15 |
| State | NJ |
| Symbol | AMRX |
| Target High Price | 19.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.16667 |
| Target Median Price | 17.0 |
| Total Cash | 286,465,984 |
| Total Cash Per Share | 0.91 |
| Total Debt | 2,689,046,016 |
| Total Revenue | 3,018,759,936 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.22 |
| Trailing P E | 59.18182 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.404625 |
| Two Hundred Day Average Change | 1.6153755 |
| Two Hundred Day Average Change Percent | 0.14164214 |
| Type Disp | Equity |
| Volume | 1,050,886 |
| Website | https://www.amneal.com |
| Zip | 8,807 |